公开(公告)号：US20220110964A1

公开(公告)日：2022-04-14

申请号：US17265386

申请日：2019-08-01

Applicant: LEMONEX INC.

Inventor： Cheol Hee WON

IPC: A61K31/7088 ,  A61K9/14 ,  C12N15/113

Abstract: A composition according to an embodiment includes porous silica particles carrying nucleic acid molecules that complementarily bind to at least a portion of thymic stromal lymphopoietin (TSLP) mRNA. The composition is capable of preventing or treating, with excellent efficiency, atopic diseases, such as bronchial asthma, allergic rhinitis, atopic dermatitis, allergic dermatitis or inflammatory skin diseases by effectively inhibiting the expression level of TSLP.

公开(公告)号：US20210230602A1

公开(公告)日：2021-07-29

申请号：US17162045

申请日：2021-01-29

Applicant: LEMONEX INC.

Inventor： Cheol Hee WON

IPC: C12N15/113 ,  A61K9/16 ,  C07K14/00 ,  A61P17/02

Abstract: A composition according to an embodiment of the present invention includes nucleic acid molecules which are capable of effectively inhibiting the expression level of connective tissue growth factor (CTGF) and collagen by RNA interference (RNAi), thereby preventing or treating a variety of fibroproliferative diseases due to overexpression of CTGF or collagen.

公开(公告)号：US20210228670A1

公开(公告)日：2021-07-29

申请号：US17258312

申请日：2019-07-09

Applicant: LEMONEX INC.

Inventor： Cheol Hee WON ,  Jun KIM

IPC: A61K36/61 ,  A23L33/105 ,  A61K9/00 ,  A61P27/02

Abstract: A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration.

公开(公告)号：US10809196B2

公开(公告)日：2020-10-20

申请号：US15765409

申请日：2016-06-15

Applicant: LEMONEX INC.

Inventor： Cheolhee Won ,  Dal-Hee Min

IPC: G01N33/53 ,  C12Q1/70 ,  G01N33/533 ,  G01N21/64 ,  C12N15/115 ,  G01N33/58 ,  C12Q1/6888 ,  C12Q1/6818 ,  C08B37/02 ,  C08B37/08 ,  C12N1/20 ,  G01N33/574 ,  A61K49/00 ,  B82Y30/00

Abstract: A quencher containing water-soluble polymer-conjugated nanomaterial effectively quenches the fluorescence of a fluorescent material-conjugated probe. In addition, a composition including the quencher and a fluorescent material-conjugated probe can detect a target material existing at a low concentration, and thus can be favorably used as a composition or kit for providing information necessary for the detection of a biomaterial or the diagnosis of a disease.

公开(公告)号：US20200009054A1

公开(公告)日：2020-01-09

申请号：US16483830

申请日：2018-02-06

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/203 ,  A61K38/17 ,  A61K31/713 ,  A61K31/711 ,  A61K39/395 ,  A61K38/46

Abstract: A bioactive substance carrier includes a bioactive substance, and porous silica particles supporting the bioactive substance and having a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US12295967B2

公开(公告)日：2025-05-13

申请号：US17051117

申请日：2019-04-24

Applicant: LEMONEX INC. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Cheol Hee Won ,  Dal Hee Min

IPC: A61K31/7036 ,  A61K31/282 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/536 ,  A61K31/5415 ,  A61K31/546 ,  A61K31/661 ,  A61K31/7048 ,  A61K38/12 ,  A61K38/14 ,  A61P31/14

Abstract: A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

公开(公告)号：US12076336B2

公开(公告)日：2024-09-03

申请号：US17536880

申请日：2021-11-29

Applicant: LEMONEX INC.

Inventor： Cheolhee Won

IPC: C07H21/02 ,  A61K31/713 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K31/713 ,  A61P35/00 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/14

Abstract: The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310.

公开(公告)号：US11701378B2

公开(公告)日：2023-07-18

申请号：US17533533

申请日：2021-11-23

Applicant: LEMONEX INC.

Inventor： Cheol Hee Won ,  Jun Kim

IPC: A61K31/7105 ,  A61K47/69 ,  A61K47/54 ,  A61P35/00 ,  A61K31/713 ,  B82Y5/00 ,  B82Y30/00 ,  B82Y40/00

CPC classification number: A61K31/7105 ,  A61K31/713 ,  A61K47/549 ,  A61K47/6923 ,  A61P35/00 ,  B82Y5/00 ,  B82Y30/00 ,  B82Y40/00 ,  C12N2310/351

Abstract: A nucleic acid carrier according to an embodiment of the present disclosure includes CpG-ODN-RNA conjugate and a porous silica particle carrying the conjugate inside pores thereof. In this regard, the nucleic acid carrier of the present invention can stably deliver loaded nucleic acid molecules to a body and release the same to a target, thereby increasing Type 1 interferon and exhibiting RNA-inherent functions.

公开(公告)号：US20220072027A1

公开(公告)日：2022-03-10

申请号：US17536880

申请日：2021-11-29

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K31/713 ,  A61P35/00 ,  C12N15/113

Abstract: The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310.

公开(公告)号：US20210309763A1

公开(公告)日：2021-10-07

申请号：US17264944

申请日：2019-07-31

Applicant: LEMONEX INC.

Inventor： Cheol Hee WON

IPC: C07K17/14 ,  A61K47/69 ,  C07K14/47

Abstract: A composition according to an embodiment of the present disclosure includes porous artificial chaperone particles having an average pore diameter of 1 to 100 nm, thereby stapling an alpha helical polypeptide to immobilize a random coiled tertiary-structure of the polypeptide into a stable alpha-helix structure, and significantly improving stability and efficiency of the polypeptide.